<DOC>
	<DOCNO>NCT01736150</DOCNO>
	<brief_summary>The study aim evaluate efficacy safety sevelamer carbonate reduce serum phosphorus serum lipid ( total LDL-cholesterol ) Chronic Kidney Disease Patients dialysis .</brief_summary>
	<brief_title>Dose-Titration Study Sevelamer Carbonate Chronic Kidney Disease ( CKD ) Patients Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>On hemodialysis regimen schedule four hour duration three time per week minimum 30 day prior Visit 1 throughout study Have central laboratory serum iPTH measurement less 1000 pg/mL Visit 1 Have central laboratory serum phosphorus measurement great 5.5 mg/dL Visit 1a Active dysphagia swallow disorder ; predisposition current bowel obstruction , ileus , severe gastrointestinal ( GI ) motility disorder include severe constipation Documented poorly control diabetes mellitus , poorly control hypertension , active vasculitis , human immunodeficiency virus infection , clinically significant unstable medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Hemodialysis</keyword>
</DOC>